European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy

On 21 November 2016, the European Commission issued a marketing authorisation valid throughout the European Union for ixazomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Ixazomib was evalu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ESMO Open
Main Authors: Tzogani, Kyriaki, Florez, Beatriz, Markey, Greg, Caleno, Mariapaola, Olimpieri, Odoardo Maria, Melchiorri, Daniela, Hovgaard, Doris Johanna, Sarac, Sinan Bardakci, Penttilä, Karri, Lapveteläinen, Tuomo, Salmonson, Tomas, Bergh, Jonas, Gisselbrecht, Christian, Pignatti, Francesco
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2019
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6735670/
https://ncbi.nlm.nih.gov/pubmed/31555488
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2019-000570
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados